Prostate adenocarcinoma

Summary

Prostate adenocarcinoma (MONDO:0005082) is a disease with 2 cohort genes and 451 clinical trials. Molecularly, PTEN Mutation confers sensitivity to PI3Kbeta Inhibitor AZD8186 + Enzalutamide + Alpelisib in Prostate Adenocarcinoma (CIViC Level D). Top therapeutic interventions include goserelin, leuprolide, and apalutamide.

At a glance

• Cohort genes: 2
• Clinical trials: 451
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostate adenocarcinoma
Mondo ID	MONDO:0005082
EFO	EFO:0000673
DOID	DOID:2526
NCIT	C2919
SNOMED CT	399490008
UMLS	C0007112
MedGen	764
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	no

Also known as: adenocarcinoma of prostate · adenocarcinoma of the prostate · prad · prostate adenocarcinoma · prostate gland adenocarcinoma

Data availability: 95 intOGen driver records.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › prostate adenocarcinoma

Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Subtypes (2): prostatic acinar adenocarcinoma, prostate adenoid cystic carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 17 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MTHFR	Orphanet:395	Homocystinuria due to methylene tetrahydrofolate reductase deficiency
MTHFR	Orphanet:563609	Isolated anencephaly
MTHFR	Orphanet:563612	Isolated exencephaly
PTEN	Orphanet:109	Bannayan-Riley-Ruvalcaba syndrome
PTEN	Orphanet:137608	Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
PTEN	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
PTEN	Orphanet:201	Cowden syndrome
PTEN	Orphanet:210548	Macrocephaly-intellectual disability-autism syndrome
PTEN	Orphanet:2969	Proteus-like syndrome
PTEN	Orphanet:494547	Squamous cell carcinoma of the hypopharynx
PTEN	Orphanet:494550	Squamous cell carcinoma of the larynx
PTEN	Orphanet:500464	Squamous cell carcinoma of the nasal cavity and paranasal sinuses
PTEN	Orphanet:500478	Squamous cell carcinoma of the oropharynx
PTEN	Orphanet:502363	Squamous cell carcinoma of the oral cavity
PTEN	Orphanet:502366	Squamous cell carcinoma of the lip
PTEN	Orphanet:65285	Lhermitte-Duclos disease
PTEN	Orphanet:79076	Juvenile polyposis of infancy

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MTHFR	HGNC:7436	ENSG00000177000	P42898	Methylenetetrahydrofolate reductase (NADPH)	civic_evidence
PTEN	HGNC:9588	ENSG00000171862	P60484	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MTHFR	Methylenetetrahydrofolate reductase (NADPH)	Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine.
PTEN	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Phosphatase	1	42.0×	0.047
Enzyme (other)	1	6.0×	0.160

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MTHFR	Enzyme (other)	yes	1.5.1.20	Mehydrof_redctse-like, Fadh2_euk, FAD-linked_oxidoreductase-like
PTEN	Phosphatase	yes	3.1.3.16	Tyr_Pase_dom, Tyr_Pase_cat, Tensin_C2-dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	1
corpus epididymis	1
sural nerve	1
calcaneal tendon	1
endothelial cell	1
sperm	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MTHFR	254	ubiquitous	marker	corpus epididymis, sural nerve, apex of heart
PTEN	256	ubiquitous	marker	sperm, endothelial cell, calcaneal tendon

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PTEN	11,626
MTHFR	3,492

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PTEN	P60484	12
MTHFR	P42898	4

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 17. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PTEN Loss of Function in Cancer	1	2855.0×	0.006	PTEN
Regulation of PTEN mRNA translation	1	571.0×	0.011	PTEN
Regulation of PTEN localization	1	519.1×	0.011	PTEN
Metabolism of folate and pterines	1	317.2×	0.013	MTHFR
Synthesis of IP3 and IP4 in the cytosol	1	211.5×	0.015	PTEN
Transcriptional Regulation by MECP2	1	158.6×	0.015	PTEN
Negative regulation of the PI3K/AKT network	1	139.3×	0.015	PTEN
Ovarian tumor domain proteases	1	139.3×	0.015	PTEN
Synthesis of PIPs at the plasma membrane	1	105.7×	0.016	PTEN
Regulation of PTEN stability and activity	1	92.1×	0.016	PTEN
Metabolism of water-soluble vitamins and cofactors	1	90.6×	0.016	MTHFR
Regulation of PTEN gene transcription	1	89.2×	0.016	PTEN
TP53 Regulates Metabolic Genes	1	64.9×	0.019	PTEN
Downstream TCR signaling	1	64.2×	0.019	PTEN
Metabolism of vitamins and cofactors	1	58.3×	0.019	MTHFR
Ub-specific processing proteases	1	26.6×	0.040	PTEN
Metabolism	1	5.8×	0.165	MTHFR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
response to vitamin B2	1	4213.0×	0.004	MTHFR
negative regulation of synaptic vesicle clustering	1	4213.0×	0.004	PTEN
S-adenosylmethionine metabolic process	1	2808.7×	0.004	MTHFR
negative regulation of keratinocyte migration	1	2808.7×	0.004	PTEN
rhythmic synaptic transmission	1	2106.5×	0.004	PTEN
obsolete methionine biosynthetic process	1	1685.2×	0.004	MTHFR
L-methionine metabolic process	1	1404.3×	0.004	MTHFR
central nervous system myelin maintenance	1	1404.3×	0.004	PTEN
response to folic acid	1	1203.7×	0.004	MTHFR
negative regulation of cell cycle G1/S phase transition	1	1203.7×	0.004	PTEN
negative regulation of wound healing, spreading of epidermal cells	1	1203.7×	0.004	PTEN
spindle assembly involved in female meiosis	1	936.2×	0.004	PTEN
central nervous system neuron axonogenesis	1	936.2×	0.004	PTEN
homocysteine metabolic process	1	936.2×	0.004	MTHFR
postsynaptic density assembly	1	936.2×	0.004	PTEN
neuron-neuron synaptic transmission	1	842.6×	0.004	PTEN
negative regulation of peptidyl-serine phosphorylation	1	842.6×	0.004	PTEN
tetrahydrofolate interconversion	1	842.6×	0.004	MTHFR
negative regulation of cell size	1	842.6×	0.004	PTEN
presynaptic membrane assembly	1	842.6×	0.004	PTEN
negative regulation of organ growth	1	702.2×	0.004	PTEN
forebrain morphogenesis	1	702.2×	0.004	PTEN
multicellular organismal response to stress	1	648.1×	0.004	PTEN
negative regulation of axonogenesis	1	648.1×	0.004	PTEN
heterochromatin organization	1	648.1×	0.004	MTHFR
cellular response to electrical stimulus	1	648.1×	0.004	PTEN
negative regulation of excitatory postsynaptic potential	1	648.1×	0.004	PTEN
maternal behavior	1	561.7×	0.004	PTEN
prepulse inhibition	1	561.7×	0.004	PTEN
locomotor rhythm	1	526.6×	0.004	PTEN

Therapeutics

Drugs indicated for this disease

10 approved, 34 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Abiraterone Acetate	Approved (phase 4)
Apalutamide	Approved (phase 4)
Cabazitaxel	Approved (phase 4)
Darolutamide	Approved (phase 4)
Dutasteride	Approved (phase 4)
Enzalutamide	Approved (phase 4)
Finasteride	Approved (phase 4)
Flutamide	Approved (phase 4)
Nilutamide	Approved (phase 4)
Relugolix	Approved (phase 4)
Abiraterone	Phase 3 (in late-stage trials)
Alendronic Acid	Phase 3 (in late-stage trials)
Atezolizumab	Phase 3 (in late-stage trials)
Atorvastatin	Phase 3 (in late-stage trials)
Atrasentan	Phase 3 (in late-stage trials)
Bevacizumab	Phase 3 (in late-stage trials)
Bicalutamide	Phase 3 (in late-stage trials)
Buserelin	Phase 3 (in late-stage trials)
CTT-1057	Phase 3 (in late-stage trials)
Cholecalciferol	Phase 3 (in late-stage trials)
Cyproterone Acetate	Phase 3 (in late-stage trials)
Dasatinib Anhydrous	Phase 3 (in late-stage trials)
Degarelix	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Estramustine	Phase 3 (in late-stage trials)
Fludrocortisone Acetate	Phase 3 (in late-stage trials)
Goserelin	Phase 3 (in late-stage trials)
Histrelin	Phase 3 (in late-stage trials)
Hydrocortisone	Phase 3 (in late-stage trials)
Leuprolide	Phase 3 (in late-stage trials)
Medroxyprogesterone Acetate	Phase 3 (in late-stage trials)
Meloxicam	Phase 3 (in late-stage trials)
Mitoxantrone	Phase 3 (in late-stage trials)
Olaparib	Phase 3 (in late-stage trials)
Opevesostat	Phase 3 (in late-stage trials)
Pembrolizumab	Phase 3 (in late-stage trials)
Perflutren	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)
Rosiglitazone	Phase 3 (in late-stage trials)
Sipuleucel-T	Phase 3 (in late-stage trials)
Sunitinib	Phase 3 (in late-stage trials)
Tasquinimod	Phase 3 (in late-stage trials)
Triptorelin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): ANTINEOPLASTON A10, Afatinib, Alisertib, Amifostine, Ascorbic Acid, Aspirin, Axitinib, Azacitidine, Cabozantinib, Calcitriol, Capivasertib, Carboplatin, Cediranib, Celecoxib, Cetuximab, Doconexent, Doxorubicin, Durvalumab, Erdafitinib, Ergocalciferol, Etoposide, Exisulind, Fenretinide, Figitumumab, Flibanserin, Fulvestrant, Furosemide, Ganetespib, Golimumab, INTERFERON ALFA-2B, Icosapent, Incomplete Freund’S Adjuvant, Indomethacin, Ipilimumab, Isosorbide, Itraconazole, Ixabepilone, Ketoconazole, Lenalidomide, Linsitinib, Lycopene, Metformin, Mifepristone, Naproxen, Neratinib, Nintedanib, Niraparib, Nivolumab, Orteronel, Paclitaxel, Paclitaxel Poliglumex, Patupilone, Pazopanib, Perifosine, Piflufolastat, Relacorilant, Rilimogene Galvacirepvec, Rintatolimod, Sargramostim, Selegiline, Siltuximab, Sodium Fluoride, Sorafenib, Sulforaphane, Talazoparib, Tanespimycin, Testosterone Cypionate, Testosterone Enanthate, Thalidomide, Tivantinib, Tocilizumab, Trebananib, Tremelimumab, Tretinoin, Trilostane, Vorinostat, Zibotentan, Zimberelimab.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MTHFR	0	0
PTEN	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PTEN	8	Binding:8

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
MTHFR	1.5.1.20, 1.5.1.53	methylenetetrahydrofolate reductase [NAD(P)H], methylenetetrahydrofolate reductase (NADPH)
PTEN	3.1.3.16, 3.1.3.67	protein-serine/threonine phosphatase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	2	MTHFR, PTEN
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MTHFR	0	—
PTEN	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 451.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	192
Not specified	135
PHASE1	48
PHASE3	32
PHASE1/PHASE2	25
EARLY_PHASE1	9
PHASE2/PHASE3	6
PHASE4	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05919329	PHASE4	RECRUITING	Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT01661166	PHASE4	COMPLETED	A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
NCT02025361	PHASE4	COMPLETED	Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
NCT05803096	PHASE4	COMPLETED	Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain
NCT01952223	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT03367702	PHASE3	ACTIVE_NOT_RECRUITING	Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT04134260	PHASE3	RECRUITING	Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04423211	PHASE3	RECRUITING	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04446117	PHASE3	ACTIVE_NOT_RECRUITING	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04455750	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04513717	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT05050084	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05796973	PHASE3	RECRUITING	Measuring Oncological Value of Exercise and Statin
NCT05946213	PHASE3	RECRUITING	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT06205316	PHASE3	RECRUITING	SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06235151	PHASE3	RECRUITING	Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06931340	PHASE3	RECRUITING	Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT07200830	PHASE3	NOT_YET_RECRUITING	Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07574489	PHASE2/PHASE3	NOT_YET_RECRUITING	Whole Versus Partial Gland Boost During Prostate SBRT
NCT00110214	PHASE3	COMPLETED	Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00182052	PHASE3	COMPLETED	Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
NCT00764166	PHASE3	UNKNOWN	A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
NCT01394263	PHASE3	COMPLETED	Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
NCT01697384	PHASE3	COMPLETED	Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
NCT01949337	PHASE3	UNKNOWN	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
NCT02175212	PHASE3	COMPLETED	Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
NCT02258087	PHASE2/PHASE3	UNKNOWN	HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.
NCT02624518	PHASE2/PHASE3	COMPLETED	68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT02673151	PHASE2/PHASE3	COMPLETED	68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
NCT02678351	PHASE2/PHASE3	COMPLETED	68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
NCT02940262	PHASE3	COMPLETED	Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
NCT03070886	PHASE2/PHASE3	COMPLETED	Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03274687	PHASE3	COMPLETED	Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NCT03327662	PHASE3	TERMINATED	Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer
NCT03404648	PHASE3	COMPLETED	Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
NCT03535675	PHASE3	TERMINATED	Muscadine Plus (MPX) In Men With Prostate Cancer
NCT03686683	PHASE3	COMPLETED	Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
NCT03739684	PHASE3	COMPLETED	Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
NCT04914195	PHASE3	COMPLETED	Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
NCT05197257	PHASE3	COMPLETED	68Ga-PSMA-11 PET in Patients With Prostate Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GOSERELIN	4	34
LEUPROLIDE	4	31
APALUTAMIDE	4	16
DEGARELIX	4	15
BICALUTAMIDE	4	13
TALAZOPARIB	4	12
ENZALUTAMIDE	4	9
GALLIUM GA 68 GOZETOTIDE	4	9
RELUGOLIX	4	8
FLUTAMIDE	4	7
ABIRATERONE ACETATE	4	6
HISTRELIN	4	6
TRIPTORELIN	4	6
CABAZITAXEL	4	5
FLOTUFOLASTAT F-18 GALLIUM	4	4
FLUCICLOVINE F18	4	4
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	4	4
PHENELZINE	4	4
SIPULEUCEL-T	4	4
ABIRATERONE	4	3
CABOZANTINIB	4	3
IXABEPILONE	4	3
NILUTAMIDE	4	3
PIFLUFOLASTAT F18	4	3
RADIUM RA 223 DICHLORIDE	4	3
ATORVASTATIN	4	2
BUSERELIN	4	2
DAROLUTAMIDE	4	2
ERDAFITINIB	4	2
GONADORELIN	4	2

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 1 predisposing, 1 prognostic.

Molecular subtype	Therapy	Effect	Level	CIViC
PTEN Mutation	PI3Kbeta Inhibitor AZD8186 + Enzalutamide + Alpelisib	Sensitivity/Response	CIViC D	EID1522